While such models are typically used with hypothetical in-silico patients, a recent approach uses a personalized model to replay recorded data of individuals with T1D with altered carbohydrate (CHO) and insulin inputs, allowing subject-specific treatment assessment for improved BG control [6]. This evidence concerns the gene INS and type 1 diabetes mellitus.